MorphoSys AG

MORNASDAQHealthcare

$18.96

+$0.45(+2.43%)

Market Cap$2.9B

P/E Ratio—

52W High$19.5

52W Low$4.185

Avg Volume83K

Open$18.38

Beta0.66

Free Cash Flow Financials Revenue

MorphoSys AG (MOR) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

MOR · free cash flow · updated Jun 9, 2026

Core FCF metrics

MOR · FCF · TTM · margin & CAGR

Free cash flow was −$298.7M for FY2023 (fiscal year ending 2023-12-31), up 21.8% year-over-year The FCF margin was -125.4%.

FY2023 Free Cash Flow−$298.7M▲ +21.8% YoY

Trailing 12M (TTM)−$282.9Mtrailing 4 quarters sum

FCF Margin-125.4%−$298.7M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

MOR · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2023Latest−$295.8M(3M)−$298.7M▲ +21.8%-125.4%

FY2022−$366.7M(15M)−$381.9M▲ +24.8%-137.3%

FY2021−$481.4M(26M)−$507.6M▼ 3508.5%-282.6%

FY2020$35.3M(49M)−$14.1M▲ +83.2%-4.3%

FY2019−$80.1M(4M)−$83.8M▼ 134.5%-116.8%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

MOR · P/FCF · FCF yield · FCF per share

MorphoSys AG (MOR) reported negative free cash flow of −$0.30B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2023 · 2023-12-31

Cash flow statement summary

MOR · cash flow statement · operating / investing / financing

For FY2023, MorphoSys AG generated −$295.8M in operating cash flow and spent 3M in capital expenditures, yielding −$298.7M in free cash flow.

Operating Activities

−$295.8M

Cash from core business operations

2023-12-31

Investing Activities

+$15.4M

CapEx, acquisitions & investments

2023-12-31

Financing Activities

+$43.0M

Buybacks, dividends & debt

2023-12-31

FCF FormulaOperating CF (−$295.8M) − |CapEx| (3M) = FCF (−$298.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

MOR vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

MorphoSys AGYOU

MOR

−$298.7M+21.8%-125.4%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

MorphoSys AG (MOR) reported free cash flow of −$298.7M for FY2023 (fiscal year ending 2023-12-31), up 21.8% year-over-year. The FCF margin was -125.4%.

Based on available data, MorphoSys AG has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $83.6M in FY2013.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

MOR free cash flow · 8 questions

MorphoSys AG free cash flow was −$298.7M for FY2023, up 21.8% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$282.9M.

MOR free cash flowMOR FCFMOR FCF 2023MOR free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · MorphoSys AG · MorphoSys AG SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026